FTC settles three claims against Teva

Generic drugmaker Teva Pharmaceuticals has committed to refrain from resolving patent infringement disputes with pay-for-delay agreements that hamper generic competitors to brand-name drugs.

Get unlimited access to all Global Competition Review content